Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 May;52(5):706-12.
doi: 10.1136/gut.52.5.706.

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

Affiliations

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

A Tannapfel et al. Gut. 2003 May.

Abstract

Background: The Raf/MEK/ERK (mitogen activated protein kinase-MAPK) signal transduction cascade is an important mediator of a number of cellular fates, including growth, proliferation, and survival. The BRAF gene, one of the human isoforms of RAF, is activated by oncogenic Ras, leading to cooperative effects in cells responding to growth factor signals.

Aims: The aim of this study was to elucidate a possible function of BRAF in liver tumours.

Methods: Mutations of BRAF and KRAS were evaluated in 25 hepatocellular carcinomas (HCC) and in 69 cholangiocarcinomas (CC) by direct DNA sequencing analyses after microdissection. The presence of active intermediates of the MAPK pathway was assessed immunohistochemically. The results obtained were correlated with histopathological variables and patient survival.

Results: Activating BRAF missense mutations were identified in 15/69 CC (22%) and in one case of tumour surrounding liver. KRAS mutations were found in 31 of 69 (45%) CC examined and in two cases of tumour surrounding non-neoplastic liver tissue. In HCC, neither BRAF nor KRAS mutations were detected. All 31 CC with KRAS mutations had an intact BRAF gene. We failed to observe a correlation between BRAF or KRAS mutations and histopathological factors or prognosis of patients.

Conclusions: Our data indicate that BRAF gene mutations are a relatively common event in CC but not in HCC. Disruption of the Raf/MEK/ERK (MAPK) kinase pathway, either by RAS or BRAF mutation, was detected in approximately 62% of all CC and is therefore one of the most frequent defects in cholangiocellular carcinogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Microdissection of cholangiocarcinoma cells. The outlined areas (A) were microdissected (B) by the laser system (Palm MicrobeamSystem) and catapulted (C), as described in materials and methods.
Figure 2
Figure 2
Mutation analysis of the BRAF gene. Electropherograms of the DNA sequences of patient Nos 9, 54, and 58 (same patients as in tables 2 and 3 ▶ ▶).
Figure 3
Figure 3
Immunostaining of the active MAPK protein. (A) Perinuclear staining (red reaction product) of tumour cells (original magnification ×60). (B) Tumour No 51 in table 2 ▶: well differentiated cholangiocarcinoma with a strong staining of active MAPK protein (original magnification ×20). (C) Tumour No 4 in table 3 ▶: poorly differentiated cholangiocarcinoma with partial mucinous differentiation. Tumour cells were positive for active MAPK to a lesser extent compared with (B) (original magnification ×20).

References

    1. Wittekind Ch. Hepatocellular carcinoma and cholangiocarcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, et al, eds. Prognostic Factors in Cancer. Berlin: Springer, 2002.
    1. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 2001;48:816–20. - PMC - PubMed
    1. Ding SF, Delhanty JD, Bowles L, et al. Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholangiocarcinoma. Br J Cancer 1993;67:1007–10. - PMC - PubMed
    1. Rao YP, Studer EJ, Stravitz RT, et al. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 2002;35:307–14. - PubMed
    1. van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50:(suppl 3):III47–53. - PMC - PubMed

Publication types

MeSH terms

Substances